4294-95-5

Usage

Uses

Used in Pharmaceutical Industry:
2-Amino-4-methoxy-benzoic acid is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications, such as antibiotics, anti-inflammatory agents, and analgesics.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Amino-4-methoxy-benzoic acid is utilized as a precursor for the production of various agrochemicals, including herbicides, insecticides, and fungicides. Its ability to form stable derivatives makes it a valuable component in the development of effective and environmentally friendly crop protection products.
Used in Specialty Chemicals:
2-Amino-4-methoxy-benzoic acid is also employed in the synthesis of specialty chemicals for various applications, such as dyes, pigments, and polymers. Its versatility in chemical reactions enables the creation of innovative products with unique properties and improved performance.
Overall, 2-Amino-4-methoxy-benzoic acid is a valuable organic building block with diverse applications across multiple industries, contributing to the development of new and improved products in pharmaceuticals, agrochemicals, and specialty chemicals.

InChI:InChI=1/C8H9NO3/c1-12-5-2-3-6(8(10)11)7(9)4-5/h2-4H,9H2,1H3,(H,10,11)

Upstream product

• 50868-78-5 2-acetamido-4-methoxybenzoic acid 
• 536-90-3 m-Anisidine 
• 17484-36-5 4-Methyl-3-nitroanisole 
• 33844-21-2 2-nitro-4-methoxybenzoic acid 
• 7440-05-3 palladium 
• 118-92-3 anthranilic acid 
• 50413-30-4 methyl 2-amino-4-methoxybenzoate 
• 153898-63-6 2-iodo-5-methoxyaniline 
• 38487-91-1 2-amino-p-anisamide 
• 621-42-1 meta-hydroxyacetanilide 
• 50868-75-2 5’-methoxy-2’-methylacetanilide 
• 96-96-8 4-methoxy-2-nitroaniline 
• 38469-83-9 4-methoxy-2-nitro-benzonitrile 
• 6966-87-6 2-(hydroxyimino)-N-(3-methoxyphenyl)acetamide 

Downstream Products

• 2142-05-4 2-(3-methoxyphenyl)-1H-isoindole-1,3(2H)-dione 
• 16064-24-7 7-methoxyquinazoline-4(3H)-one 
• 861546-94-3 2-(carboxymethyl-amino)-4-methoxy-benzoic acid 
• 102879-57-2 4-methoxy-2-methylamino-benzoic acid 
• 38918-51-3 7-methoxy-2-[4-methoxy-2-(toluene-4-sulfonylamino)-phenyl]-benzo[d][1,3]oxazin-4-one 
• 766-85-8 3-methoxy-1-iodobenzene 
• 54435-09-5 2-iodo-4-methoxybenzoic acid 
• 103203-39-0 2-[(carboxymethyl)thio]-4-methoxybenzoic acid 
• 128076-63-1 7-methoxy-2H-benzo[d][1,3]oxazine-2,4(1H)-dione 
• 50413-30-4 methyl 2-amino-4-methoxybenzoate 
• 62484-12-2 6-methoxy-quinazoline-2,4-diol 
• 62484-12-2 7-methoxyquinazoline-2,4(1H,3H)-dione 
• 1265087-49-7 4-methoxy-6-(2-phenylsulfanyl-acetylamino)benzoic acid 
• 1384487-62-0 2-amino-4-methoxy-N-(prop-2-yn-1-yl)benzamide 

Relevant academic research and scientific papers

Selenium-catalyzed intramolecular atom- And redox-economical transformation ofo-nitrotoluenes into anthranilic acids

Anthranilic acids (AAs) are significant basic chemicals used in pharmaceuticals, agrochemicals, dyes, fragrances,etc. Superfluous steps are always involved in obtaining AAs. Herein, we demonstrate a straightforward strategy to transform abundanto-nitrotoluenes into biologically and pharmaceutically significant AAs without any extra reductants, oxidants and protecting groups. Various sensitive groups, such as halogens, sulfide, aldehyde, pyridines, quinolines,etc., can be tolerated in this transformation. A hundred-gram-scale operation is realized efficiently with almost quantitative selenium recycling. Further mechanistic studies and DFT calculations disclosed the proposed atom-exchange processes and the key roles of the selenium species.

Discovery of Novel Tacrine-Pyrimidone Hybrids as Potent Dual AChE/GSK-3 Inhibitors for the Treatment of Alzheimer's Disease

Based on a multitarget strategy, a series of novel tacrine-pyrimidone hybrids were identified for the potential treatment of Alzheimer's disease (AD). Biological evaluation results demonstrated that these hybrids exhibited significant inhibitory activities toward acetylcholinesterase (AChE) and glycogen synthase kinase 3 (GSK-3). The optimal compound 27g possessed excellent dual AChE/GSK-3 inhibition both in terms of potency and equilibrium (AChE: IC50 = 51.1 nM; GSK-3β: IC50 = 89.3 nM) and displayed significant amelioration on cognitive deficits in scopolamine-induced amnesia mice and efficient reduction against phosphorylation of tau protein on Ser-199 and Ser-396 sites in glyceraldehyde (GA)-stimulated differentiated SH-SY5Y cells. Furthermore, compound 27g exhibited eligible pharmacokinetic properties, good kinase selectivity, and moderate neuroprotection against GA-induced reduction in cell viability and neurite damage in SH-SY5Y-derived neurons. The multifunctional profiles of compound 27g suggest that it deserves further investigation as a promising lead for the prospective treatment of AD.

Antituberculosis Activity of the Antimalaria Cytochrome bcc Oxidase Inhibitor SCR0911

The ability to respire and generate adenosine triphosphate (ATP) is essential for the physiology, persistence, and pathogenicity of Mycobacterium tuberculosis, which causes tuberculosis. By employing a lead repurposing strategy, the malarial cytochrome bc

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of diseases or disorders that are susceptible to administration of a BET inhibitor.

NOVEL ANTI-INFLAMMATORY AGENTS

Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.

Discovery of potent CCR4 antagonists: Synthesis and structure-activity relationship study of 2,4-diaminoquinazolines

A new series of quinazolines that function as CCR4 antagonists were discovered during the screening of our corporate compound libraries. Subsequent compound optimization elucidated the structure-activity relationships and led the identification of 2-(1,4′-bipiperidine-1′-yl)-N-cycloheptyl-6,7-dimethoxyquinazolin-4-amine 14a, which showed potent inhibition in the [35S]GTPγS-binding assay (IC50 = 18 nM). This compound also inhibited the chemotaxis of human and mouse CCR4-expressing cells (IC50 = 140 nM, 39 nM).

CHEMICAL COMPOUNDS

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinethione derivatives as selective estrogen receptor beta modulators

On the basis of the structure of genistein, a new series of 3-arylquinazolines was prepared and tested for their estrogen receptor (ER) α and β affinities. 5,7-Dihydroxy-3-(4-hydroxyphenyl)-4(3H)- quinazolinone (1aa) acts as an agonist on both ER subtypes. It has 62-fold higher binding affinity [IC50(ERβ) = 179 nM] and 38-fold higher functional potency in a transcription assay [EC50(ERβ) = 76 nM] with ERβ than with ERα, thus improving upon the selectivity of genistein. All of the analogues showed preferential binding affinity for ERβ. Many are also more potent in activating transcription by ERβ than by ERα. Transformation of the C=O functionality at position 4 into a C=S group provided 5,7-dihydroxy-3-(4-hydroxyphenyl)-4(3H)-quinazolinethione (1ba), which acts as an agonist on both ER subtypes but has 56-fold higher binding affinity for ERβ over ERα [IC50(ERβ) = 47 nM] and 215-fold higher potency in the transcription assay [EC50(ERβ) = 13 nM]. These ERβ-selective compounds may represent valuable tools in understanding the differences in structure and biological function of ERβ and ERα.

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.